Tirzepatide (10mg Vial) Dosage Protocol

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

Tirzepatide is a dual GLP-1/GIP receptor agonist — it engages two incretin pathways to curb appetite and improve glycemic control[1] — and has been studied for substantial weight loss and broad metabolic improvement in obesity and type 2 diabetes[2][3]. A long half-life of roughly 6 days makes a single weekly subcutaneous injection practical, while gradual titration keeps tolerability high from the first dose[1][4].

Add 2.0 mL bacteriostatic water to one 10 mg vial → final concentration: 5 mg/mL.
2.5–15 mg once weekly (gradual 4-week titration).
At 5 mg/mL, 1 mg = 0.20 mL = 20 units on a U-100 insulin syringe.
Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Important: Read the Prep & Injection Guide first — it covers the preparation and safety basics that every protocol on this site assumes.

Dosing & Reconstitution Guide

Reconstitution and accurate weekly dosing, step by step

Standard / Gradual Titration Approach (2 mL = 5 mg/mL)

Week(s)	Weekly Dose (mg)	Total weekly volume (U-100 units / mL)
Weeks 1–4	2.5 mg	50 units (0.50 mL) × 1 injection
Weeks 5–8	5 mg	100 units (1.0 mL) × 1 injection
Weeks 9–12	7.5 mg	75 units (0.75 mL) × 2 injections
Weeks 13–16	10 mg	100 units (1.0 mL) × 2 injections

Reconstitute: Add 2.0 mL bacteriostatic water to one 10 mg vial → final concentration: 5 mg/mL.
Typical weekly range: 2.5–15 mg once weekly (gradual 4-week titration).
Easy measuring: At 5 mg/mL, 1 mg = 0.20 mL = 20 units on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Frequency: one subcutaneous injection each week. The schedule mirrors the clinical-trial protocols that drove substantial weight loss — around 20% of body weight over 72 weeks on the 15 mg dose[2] — while holding gastrointestinal effects down through gradual escalation[1][4]. Opening at 2 mg weekly rather than 4 mg markedly softens early GI effects, and any higher weekly dose simply calls for more than one vial or a split across two sites.

Reconstitution Steps

Pull 2.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly against the vial’s inner wall to avoid foaming.
Swirl or roll gently until fully dissolved — don’t shake hard.
Note the mixing date and store at 2–8 °C (35.6–46.4 °F), shielded from light.
At 5 mg/mL, the 7.5 mg and 10 mg doses exceed a single U-100 syringe (100 units / 1.0 mL) and are split into two injections, while lower doses fit in one shot. Draw from more than one vial as the dose rises.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume a 12–48 week course of weekly injections, titrated gradually up to the maintenance dose.

Vial use scales with the weekly titration schedule.
8 weeks (2.5→5 mg/wk): ~3 vials
12 weeks (2.5→7.5 mg/wk): ~6 vials
16 weeks (2.5→10 mg/wk): ~10 vials
Per week: 1 syringe (once-weekly dosing)
12 weeks: 12 syringes
24 weeks: 24 syringes
48 weeks: 48 syringes
Use 2.0 mL per vial for reconstitution.
8 weeks (3 vials): 6 mL → 1 × 10 mL bottle
12 weeks (6 vials): 12 mL → 2 × 10 mL bottles
16 weeks (10 vials): 20 mL → 2 × 10 mL bottles
One for the vial stopper + one for the injection site each week.
Per week: 2 swabs
12 weeks: 24 swabs → 1 × 100-count box
24 weeks: 48 swabs → 1 × 100-count box
48 weeks: 96 swabs → 1 × 100-count box

Protocol Overview

The once-weekly regimen at a glance, drawn from the clinical-trial protocols.

▪Goal: Drive substantial weight loss (up to ~20% of body weight) and stronger metabolic markers through dual GLP-1/GIP receptor agonism[2][5].
▪Schedule: One subcutaneous injection a week for 12+ weeks, with the dose raised gradually.
▪Dose Range: 2.5–15 mg weekly, titrated in 2.5 mg steps every 4 weeks[1][3].
▪Reconstitution: 2.0 mL bacteriostatic water per 10 mg vial produces 5 mg/mL — handy for precise 2.5–15 mg steps.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.

Dosing Protocol

The week-by-week titration, mapped to the clinical-trial dosing.

▪Start: 2.5 mg weekly for the first 4 weeks to settle tolerability[1][4].
▪Escalation: Step up to 5 mg for Weeks 5–8, then 7.5 mg for Weeks 9–12[1].
▪Maintenance: 10 mg weekly from Week 13; some protocols titrate further to 12.5–15 mg if well tolerated[2].
▪Frequency: Once a week, subcutaneous — holding the same day and time each week aids consistency.
▪Cycle Length: Roughly 16–20 weeks to finish escalation; trials ran to 72 weeks with continued, progressive weight loss[2].
▪Timing: Any steady weekly schedule works; change the injection site with each dose.

Storage Instructions

Correct storage is what preserves the peptide’s stability and potency.

▪Lyophilized: Hold at −20 °C (−4 °F) or colder for long-term keeping; shield from moisture and light[11][12].
▪Reconstituted: Chill at 2–8 °C (35.6–46.4 °F) as soon as it’s mixed and use within 2–4 weeks to keep stability and potency[11].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form; keep the mixed solution clear of heat and direct sun.
▪Aliquoting: To store beyond 4 weeks, divide the unused portion into aliquots and freeze; steer clear of repeated freeze–thaw cycles, which cause degradation[12].

Important Notes

Practical points that keep weekly administration safe and consistent.

▪Weekly consistency: Lock in one day and time for the weekly injection and keep to it for the whole protocol.
▪Gradual titration is essential: Opening at 2 mg weekly instead of a higher dose markedly lowers the odds of early gastrointestinal effects[4].
▪Syringe use: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward[14].
▪Injection site rotation: Move sites week to week (abdomen, thighs, upper arms), keeping each shot at least 1 inch from the last to limit irritation and prevent lipohypertrophy[15].
▪Large volumes: When a dose needs more than 1.0 mL (>100 units), divide it across sites or draw from more than one reconstituted vial.
▪Side-effect monitoring: Mild nausea or stomach upset is normal while escalating; if it becomes notable, hold the current dose longer before stepping up.

How This Works

Tirzepatide is a dual GLP-1/GIP receptor agonist: it activates both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) incretin receptors, which together regulate appetite, glucose-dependent insulin release and glucagon[1][5]. These complementary receptor actions reduce appetite and energy intake, slow gastric emptying, and improve glucose regulation, which together drive steady weight loss.

GLP-1-receptor activation curbs appetite, slows gastric emptying and boosts glucose-dependent insulin release — together these cut food intake and steady blood sugar[5][8]. Together, they add up to a profound metabolic effect.
With an extended half-life of ~6 days, a single weekly dose holds therapeutic levels steady between injections[1].
In trials, participants on the highest weekly doses lost on average around 20% of body weight over 72 weeks[2]. In adults with type 2 diabetes, the higher doses produced strong weight loss alongside HbA1c reductions of up to ~2.4% versus placebo[3].
In the SURMOUNT-1 phase-3 trial, tirzepatide produced dose-dependent weight loss reaching about ~21% of total body weight at the 15 mg dose, substantially more than placebo, with gastrointestinal symptoms the most common adverse events[6][7].

Lifestyle Factors

Habits that work alongside the protocol to protect results and ease the transition.

▪Nutrition: Eat a balanced, protein-forward diet (1.0–1.2 g/kg body weight) to hold on to lean mass while losing weight[10].
▪Hydration: Keep fluids up, particularly while titrating, when GI effects peak.
▪Physical activity: Pair resistance training (2–3×/week) with moderate cardio to aid metabolic adaptation and protect muscle.
▪Sleep & stress: Aim for 7–9 hours of solid sleep and manage stress to support hormonal balance and stay on track.
▪Meal timing: Smaller, more frequent meals help some people handle GI effects during early titration.

Potential Benefits & Side Effects

What human phase 2 and phase 3 trials have reported.

▪Substantial weight loss: Around 20% body-weight reduction by 72 weeks on the 15 mg dose[2].
▪Glycemic improvement: Marked HbA1c drops (about 2.0%) in adults with type 2 diabetes[3].
▪Metabolic benefits: Gains in lipid profile, blood pressure, and cardiovascular risk markers[1][5].
▪Convenient dosing: A single weekly subcutaneous dose is easier to stick with than daily regimens[1].
▪Gastrointestinal effects: Nausea, diarrhea, vomiting, and constipation top the list of adverse events; usually mild-to-moderate and easing with time[2][4].
▪Beginning at 2 mg weekly rather than 4 mg sharply cuts early GI events[4].
▪Injection site reactions: Mild redness, swelling, or soreness can show up at the site; rotating sites keeps it minimal.
▪Overall safety profile: Pooled trial data showed no meaningful rise in overall adverse events versus placebo[6][7].

Injection Technique

Subcutaneous injection technique, following established clinical practice and CDC guidance[13][14].

▪Wash your hands well with soap and water[14].
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Pick a site (abdomen, thigh, or upper arm) and wipe it with a fresh alcohol swab, letting it dry fully[13].
▪Carefully draw the intended dose, then check for air bubbles and push any out.
▪Pinch about a 1-inch fold of skin between thumb and forefinger[15].
▪Insert the needle into the pinch at a 90-degree angle (45 degrees if the fat layer is thin)[13][14].
▪Skip aspiration for subcutaneous shots — it isn’t needed and can add discomfort[13].
▪Press the plunger slowly and steadily until it’s fully down.
▪Pull the needle straight out and, if needed, press lightly with clean gauze.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle[14].
▪Put the reconstituted vial back in the fridge right away.
▪Shift the site each week (at least 1 inch over) to prevent lipohypertrophy[15].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity Tirzepatide (10 mg vials), we point researchers to Prime Lab Peptides.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for Tirzepatide 10mg.

Tirzepatide (10mg Vial) Dosage Protocol Open source
1 New England Journal of Medicine (2023) Once-Weekly Tirzepatide for Weight Management (SURMOUNT program; 72-week results) View Source ↗ Open source
2 JAMA Network (2023) Tirzepatide (SURMOUNT) obesity trials: efficacy and safety data (~20% weight loss at 15 mg weekly) View Source ↗ Open source
3 The Lancet (2023) Tirzepatide in type 2 diabetes: Phase 2 trial (weight loss and glycemic outcomes at 36 weeks) View Source ↗ Open source
4 PubMed / NEJM (2023) Tirzepatide dosing and tolerability: starting at 2 mg vs 4 mg reduces GI adverse events View Source ↗ Open source
5 Metabolites (PMC, 2025) Tirzepatide—A Game Changer in Obesity Pharmacotherapy (comprehensive review of mechanism and trials) View Source ↗ Open source
6 New England Journal of Medicine (2022) Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1, NEJM 2022) View Source ↗ Open source
7 PubMed (2025) Meta-analysis: Tirzepatide achieves ~14% greater weight reduction vs placebo with no increase in adverse events View Source ↗ Open source
8 Molecular Metabolism (2025) Preclinical tri-agonist NN1706 (related compound): mechanism and pharmacokinetics View Source ↗ Open source
9 Nature Reviews Endocrinology (2024) Dual GIP/GLP-1 receptor agonists for obesity and diabetes: a clinical landscape review View Source ↗ Open source
10 Journal of Cachexia, Sarcopenia and Muscle (PMC) Protein requirements during weight loss: preserving lean mass View Source ↗ Open source
11 GenScript Peptide Storage and Handling Guidelines (technical bulletin for lyophilized and reconstituted peptides) View Source ↗ Open source
12 Bachem Handling and Storage Guidelines for Peptides (technical article on stability and freeze-thaw cycles) View Source ↗ Open source
13 Centers for Disease Control and Prevention (CDC) Vaccine Administration: Subcutaneous Injection (technique, angle, and site guidance) View Source ↗ Open source
14 NCBI Bookshelf Injection Administration Best Practices (aseptic technique, sharps disposal, and safety) View Source ↗ Open source
15 Pharmacologic Considerations of the Subcutaneous Route (PMC) Subcutaneous injection technique and site rotation to prevent lipohypertrophy View Source ↗ Open source
16 Prime Lab Peptides Tirzepatide (10 mg) product page (quality documentation and specifications) View Source ↗ Open source